Topical ruxolitinib: A new treatment for vitiligo

Tavoletti, Gianluca; Avallone, Gianluca; Conforti, Claudio; Roccuzzo, Gabriele; Maronese, Carlo Alberto; Mattioli, Milena; Quaglino, Pietro; Zalaudek, Iris; Marzano, Angelo Valerio; Ribero, Simone; Alberti‐Violetti, Silvia

doi:10.1111/jdv.19162

Cited by 14 publications

(4 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ruxolitinib cream is a JAK1 and JAK2 inhibitor that was approved by the FDA after the assessment of its efficacy and safety in many studies [53].…”

Section: Jak Inhibitors-ruxolitinibmentioning

confidence: 99%

Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics

Pala,

Ribero,

Quaglino

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

Vitiligo, the most prevalent skin depigmenting disease, is characterized by the selective loss of melanocytes, impacting patients’ quality of life significantly. This autoimmune disorder progresses through a complex interplay of genetic and non-genetic factors, posing challenges in comprehending its pathogenesis and devising effective treatment strategies for achieving remission. Existing conventional therapeutic approaches, such as topical and oral corticosteroids, calcineurin inhibitors, and phototherapy, lack specificity, offer modest efficacy, and may entail potential adverse effects. Consequently, there is a pressing need for a more nuanced understanding of vitiligo’s pathogenesis to pave the way for targeted therapeutic innovations. This review aims to provide a comprehensive overview of recent developments and findings concerning Januse Kinase (JAK) inhibitors and biologics tested in vitiligo patients. JAK inhibitors have exhibited promising results, showcasing both efficacy and tolerability. In contrast, the outcomes of biologics treatment have been more varied. However, to establish a clearer understanding of which specific pathways to target for a more effective approach to vitiligo, additional in vitro studies and extensive clinical research involving a larger population are imperative.

show abstract

“…Ruxolitinib cream is a JAK1 and JAK2 inhibitor that was approved by the FDA after the assessment of its efficacy and safety in many studies [53].…”

Section: Jak Inhibitors-ruxolitinibmentioning

confidence: 99%

Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics

Pala,

Ribero,

Quaglino

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…These side effects can range from mild skin irritation to more severe complications such as photosensitivity reactions or systemic effects like nausea and headache [ 15 , 16 ]. Additionally, vitiligo patients often experience relapses, even after successful prior treatments, and different treatment methods yield varying responses [ 17 ]. The limitations of existing treatments underscore the need for innovative approaches.…”

Section: Introductionmentioning

confidence: 99%

Transcutaneous Auricular Vagus Nerve Stimulation Alleviates Monobenzone-Induced Vitiligo in Mice

Luo,

Meng,

et al. 2024

IJMS

View full text Add to dashboard Cite

Vitiligo is a complex skin disorder that involves oxidative stress and inflammatory responses and currently lacks a definitive cure. Transcutaneous auricular vagus nerve stimulation (taVNS) is a noninvasive method for targeting the auricular branch of the vagus nerve and has gained widespread attention for potential intervention in the autonomic nervous system. Although previous research has suggested that vagus nerve stimulation can potentially inhibit inflammatory responses, its specific role and mechanisms in vitiligo treatment remain unknown. This study aimed to explore the therapeutic effects of taVNS in a mouse model of vitiligo induced by monobenzone. Initially, a quantitative assessment of the treatment effects on vitiligo mice was conducted using a scoring system, revealing that taVNS significantly alleviated symptoms, particularly by reducing the depigmented areas. Subsequent immunohistochemical analysis revealed the impact of taVNS treatment on melanocyte granules, mitigating pigment loss in the skin of monobenzone-induced vitiligo mice. Further analysis indicated that taVNS exerted its therapeutic effects through multiple mechanisms, including the regulation of oxidative stress, enhancement of antioxidant capacity, promotion of tyrosine synthesis, and suppression of inflammatory responses. The conclusions of this study not only emphasize the potential value of taVNS in vitiligo therapy, but also lay a foundation for future research into the mechanisms and clinical applications of taVNS.

show abstract

“…Currently, the only topical treatment approved for vitiligo by the U.S. Food and Drug Administration is ruxolitinib [ 9 ]. Despite approval, the availability of ruxolitinib is limited, and real-life data are still lacking.…”

Section: Introductionmentioning

confidence: 99%

Vitiligo Treated with Combined Piperine-Based Topical Treatment and Narrowband Ultraviolet B Therapy: Follow-Up with Reflectance Confocal Microscopy

Bertoli,

Chester,

Cortelazzi

et al. 2024

Diagnostics

View full text Add to dashboard Cite

Background: Reflectance confocal microscopy (RCM) has a defined in vivo morphology of vitiligo and re-pigmentation. Combination therapies seem more effective than monotherapies. Objective: We aim to describe the clinical and RCM features of re-pigmentation with combined narrowband ultraviolet B (NB-UVB) and piperine-based topical treatment in localized vitiligo. Methods: Eight patients enrolled at a single center received combined treatment: topical treatment was applied twice daily + NB-UVB twice weekly for 2 × 2-month periods. Clinical changes were analyzed by the Vitiligo Noticeability Scale (VNS) and percentage of re-pigmentation. The evaluator agreement was assessed. Predefined RCM features had the presence/absence of (i) blood vessels, (ii) dendritic cells, and the quantity of (i) an irregular honeycombed pattern and (ii) non-pigmented papillae. Clinical and RCM monitoring was performed at the baseline, 2, 3, 5, and 7 months. Results: Macules were “slightly less noticeable” with 25–50% re-pigmentation. Irregular honeycomb patterns and non-pigmented papillae were significantly less frequently observed, and in less extended areas (T1 vs. T2, p = 0.039; T0 vs. T1, p = 0.005 and T2 vs. T4, p = 0.033). Dendritic cells and blood vessels improved, with significant changes in blood vessels (T1 vs. T2, p = 0.005 and T3 vs. T4, p = 0.008). Conclusions: RCM confirms the morphological changes induced by combined treatment for localized vitiligo.

show abstract

Topical ruxolitinib: A new treatment for vitiligo

Cited by 14 publications

References 47 publications

Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics

Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics

Transcutaneous Auricular Vagus Nerve Stimulation Alleviates Monobenzone-Induced Vitiligo in Mice

Vitiligo Treated with Combined Piperine-Based Topical Treatment and Narrowband Ultraviolet B Therapy: Follow-Up with Reflectance Confocal Microscopy

Contact Info

Product

Resources

About